From: Genetics of type 2 diabetes mellitus in Indian and Global Population: A Review
Nos. | Gene | SNP (P/R) | Risk allele/non-risk allele | OR (95% CI), P value | Population | Type of study |
---|---|---|---|---|---|---|
1 | Peroxisome proliferator-activated receptor gamma (PPARG) | C/G [53] | India—1.37 (1.19–1.59), 1.6 × 10−5 [53] Europeans—1.14 (1.08–1.20), 1.7 * 10–6 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] | |
 |  |  |  | 0.7 (0.50–0.99), 0.046 [24] | Hyderabad [24] | Observational case–control study [24] |
 |  |  | CC + CG versus GG [4] | 0.13 (0.03–0.56), 0.0007 [4] | Sikh Indians (Punjab, Haryana, Himachal Pradesh, Delhi and Jammu and Kashmir [53]) | Observational case–control study [53] |
 |  | 2. rs11715073 [4] (P) | CC + CG versus GG [4] | 0.52 (0.31–0.86), 0. .010 [4] | Sikh Indians (Punjab, Haryana, Himachal Pradesh, Delhi and Jammu and Kashmir [4]) | Observational case–control study [4] |
 |  | 3. rs2972164 [4] (R) | CC versus CT + TT | 1.30 (1.00–1.68), 0. .048 [4] | Sikh Indians (Punjab, Haryana, Himachal Pradesh, Delhi and Jammu and Kashmir [4]) | Observational case–control study [4] |
2 | Potassium Inwardly Rectifying Channel Subfamily J Member 11 (KCNJ11) | T/C | India—1.39 (1.26–1.54), 6.7 * 10–11 [53] Europeans—1.14 (1.10–1.19), 6.7 * 10–11 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] | |
 |  |  |  | 1.14 (1.10–1.1), 5 * 10–11 [27] | UK [27] | Observational case–control study [27] |
 |  | 2. rs5215 [21] (P) | CC | 0.42 (0.28–0.62) P-0.0001[21] | South Indian [21] | Observational case–control study [21] |
3 | Transcription factor 7-like 2 (TCF7L2) | T/C | India—1.89 (1.71–2.09), 4.6 * 10–34 [53] Europeans—1.37 (1.31–1.43),1*10–48 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] | |
 |  |  |  | 1.32 (1.22–1.43),5.3 * 10–13 [16] | Africa [16] | GWAS [16] |
 |  |  |  | 1.44 (1.17–1.78),2.05–08 [54] | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
 |  |  |  | 1.35 (1.19–1.54), 6.1 × 10−6 [18] | Sri Lanka [18] | Observational case–control study [18] |
 |  |  |  | 1.62 (1.17–2.25), 0.003 [55] | Egypt [55] | Observational case–control study [55] |
 |  |  | CT | 1.99 (1.49–2.64), < 0.001 [24] | Hyderabad [24] | Observational case–control study [24] |
 |  |  | TT | 3.58 (2.09–6.13), < 0.001 [24] | Hyderabad [24] | Observational case–control study [24] |
 |  | G/T | 2.06 (1.45–2.93), < 0.0001 [55] | Egypt [55] | Observational case–control study [55] | |
 |  |  |  | 2.14 (1.01–4.55),0.004 [56] | Mexico [56] | Observational study [56] |
 |  |  |  | 1.3376, P value-1.46E-06 [54] | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
 |  |  | GG | Chi-square-30.73 < .0001[56] | Mexico [56] | Observational study [56] |
4 | Solute carrier family 30, member 8 (SLC30A8) | C/T | Indians—1.34 (1.20–1.50), 3.4 * 10–7 Europeans—1.12 (1.07–1.16), 5.3 * 10–8 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study | |
 |  |  |  | 1.33 (1.14–1.55), 3.0 × 10−4 [18] | Sri Lanka [18] | Observational case–control study [18] |
 |  |  |  | 3.24 (1.20–13.39) [19] | Germany [19] | Observational case–control study [19] |
5 | Haematopoietically expressed homeobox protein (HHEX) | G/A | Indians—1.27 (1.16–1.39), 5.7 * 10–7 Europeans—1.13 (1.09–1.17), 5.7 * 10–10 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] | |
 |  |  |  | 120.82 (17–inf*), < 0.001 [57] | Iran [57] | Observational case–control study [57] |
 |  |  |  | 1.262, 1.44–05 [54] | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
 |  |  | GG | 32.32 (13–91), < 0.001 [57] | Iran [57] | Observational case–control study [57] |
 |  | C/T | Chi-square-19.94, 1.55–03 [58] | Korea [58] | GWAS [58] | |
 |  |  |  | 1.2943, 1.83–06 [54] | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
6 | Cyclin-dependent kinase inhibitor 2A (CDKN2A) | 1. rs10811661 [53] (R) | T/C | Indians—1.37 (1.18–1.59), 5.1 * 10–5 [53] Europeans—1.20 (1.14–1.25),7.8 * 10–25 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] |
7 | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | 1. rs4402960 [53] (R) | T/G | Indians—1.20 (1.09–1.33), 2.6 * 10–3 Europeans—1.14 (1.11–1.18), 8.9 * 10–36 [52] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] |
8 | Cdk5 regulatory associated protein 1-like 1 (CDKAL1) | 1. rs10946398 [53] (R) | C/A | Indians—1.18 (1.07–1.32), 1.6 * 10–3 Europeans—1.12 (1.08–1.16), 4.1 * 10–11 [53] | India (Delhi, Pune); Europeans [53] | Observational case–control study [53] |
 |  | 2. rs7756992 [24] | GG | 1.97 (1.09–3.56), 0.025 [24] | Hyderabad [24] | Observational case–control study [24] |
 |  | 3. rs7754840 [59] (R) | GG | 1.36 (1.02–1.82), 0.0349 [59] | Han Chinese [59] | Observational case–control study [59] |
 |  |  | CC | 2.03 (1.42–2.89), 9.07 * 10–5 [59] | Han Chinese [59] | Observational case–control study [59] |
 |  | 4. rs4712523 [59] (R) | AG | 1.38 (1.03–1.84), 0.0291[59] | Han Chinese [59] | Observational case–control study [59] |
 |  |  | GG | 1.97 (1.39–2.81) 1.49 × 10–4 [59] | Han Chinese [59] | Observational case–control study [59] |
 |  | 5. rs4712524 [59] (R) | AA | 1.42 (1.06–1.90),0.0189 [59] | Han Chinese [59] | Observational case–control study [59] |
 |  |  | GG | 1.85 (1.30–2.62) 5.85 * 10–4 [59] | Han Chinese [59] | Observational case–control study [59] |
9 | Alkylglycerol Monooxygenase (AGMO) | 1. rs73284431 [16] (R) | G /C | 1.48 (1.30–1.69), 5.2 * 10–9 [16] | Africa [16] | Observational case–control study [16] |
10 | Adiponectin, C1Q And Collagen Domain Containing (ADIPOQ) | 1. rs182052 [53] (R) | GG | 1.23 (1.02–1.48), 0.027 [53] | Sikh Indians (Punjab, Haryana, Himachal Pradesh, Delhi and Jammu and Kashmir [53]) | Observational case–control study [53] |
 |  | 2. rs7649121 [53] (R) | AA | 1.36 (1.03–1.79), 0.029 [53] | Sikh Indians (Punjab, Haryana, Himachal Pradesh, Delhi and Jammu and Kashmir [53]) | Observational case–control study [53] |
 |  | 3. rs1501299 [47] (R) | GG [47] | 2.350 (1.231–4.486), 0.010 [47] | Jordan [47] | Observational study [47] |
 |  |  | TT [47] | 4.774 (1.551–14.693) 0.006 [47] | Jordan [47] | Observational study [p47] |
11 | Insulin-Degrading Enzyme (IDE) | 1. rs1887922 [54] (R) | T/C [54] | 1.3423, 5.44–05 | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
12 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) | 1. rs1044498 [54] (R) | A/C [54] | 1.341,4.24–05 [55] | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
13 | Alpha-Ketoglutarate-Dependent Dioxygenase (FTO) | 1. rs9939609 [54] (R) | T/A [54] | 1.2906, 7.38–06 [54] | India—Punjab, Jammu and Kashmir, Orissa [54] | Observational case–control study [54] |
 |  | 2. rs9940128 [26] (R) | AG | 1.48 (1.16–1.89), 0.001 [26] | Chennai [26] | Observational case–control study [26] |
 |  |  | GG | 2.04 (1.42–2.94), < 0.0001[26] | Chennai [26] | Observational case–control study [26] |
 |  | 3. rs1588413 [26] (R) | CT | 1.81 (1.43–2.31), < 0.0001[26] | Chennai [26] | Observational case–control study [26] |
 |  |  | TT | 1.86 (1.18–2.92), 0.007 [26] | Chennai [26] | Observational case–control study [26] |
 |  | 4. rs11076023 [26] (P) | AT | 0.70 (0.53–0.92), 0.01 [26] | Chennai [26] | Observational case–control study [26] |
 |  |  | TT | 0.64 (0.46–0.89), 0.008 [26] | Chennai [26] | Observational case–control study [26] |
14 | Cyclin-Dependent Kinase Inhibitor 2B CDKN2B | 1. rs564398 [27] (R) | C/T | 1.12,1.2 × 10−7 [27] | UK population [27] | Observational case–control study [27] |
15 | Solute Carrier Family 16 Member 11 (SLC16A11) | 1. rs77086571[27] (R) | C/T | 1.29,5.4 × 10−12[27] | UK population [27] | Observational case–control study [27] |
16 | Dual specificity phosphatase 9 (DUSP9) | 1. rs5945326 [19] (R) |  | 2.04 (1.14–3.89) [19] | European population [19] | Observational study [19] |
17 | Kruppel-like factor 14 (KLF14) | 1. rs972283 [19] (R) |  | 3.45 (1.69–8.38) [19] | European population [19] | Observational study [19] |
18 | Ribosomal protein S6 kinase alpha-1 (RPS6KA1) | 1. rs1002487 [48] (R) | C | 2.89–11 [48] | Arab [48] | GWAS [48] |
19 | Calcium-dependent secretion activator (CADPS) | 1. rs487321 [48] (R) | A | 2.054–12 [48] | Arab [48] | GWAS [48] |
20 | Valyl-tRNA synthetase (VARS) | 1. rs707927 [48] (R) | G | 1.61–09 [48] | Arab [48] | GWAS [48] |
21 | DExH-Box Helicase 58 (DHX 58) | 1. rs12600570 (R) [48] (P) | T | 1.48–03 [48] | Arab [48] | GWAS [48] |
22 | Retinoic acid-inducible gene (STRA6) | 1. rs974456 [17] (P) | C/T | 0.79 (0.69–0.91), 0.003 [17] | Kerala [17] | Observational case–control study [69] |
 |  | 1. rs736118 [17] (P) | G/A | 0.81 (0.71–0.93), 0.01 [17] | Kerala [17] | Observational case–control study [69] |
 |  | 1. rs4886578 [17] (P) | G/A | 0.74 (0.62–0.89), 0.0009 [17] | Kerala [17] | Observational case–control study [17] |
23 | Forkhead box protein A2 (FOXA2) | Polymorphism [60] (R) | A | 1.44 (1.22–1.70), 1.5 9 10–5 [60] | North Indian [60] | Observational cohort study [60] |